Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
RZ-001, an RNA editing-based gene therapy, demonstrated tolerability and disease control in 10 glioblastoma patients during Phase 1/2a trials, with no dose-limiting toxicity and several patients achieving tumor recurrence inhibition beyond six months. Early safety and efficacy signals support continued development of this targeted approach to a treatment-resistant malignancy.
Humacyte's acellular tissue-engineered vessel achieved superior outcomes in women requiring dialysis access, demonstrating 220 catheter-free days versus 129 for standard arteriovenous fistula, with infection rates of 6 per 100 patient-years compared to 23 per 100 patient-years. This represents a clinically meaningful advance in vascular access durability and safety for end-stage renal disease patients.
Ofirnoflast, an oral NEK7 modulator that regulates NLRP3 inflammasome activation, achieved hematologic improvement in 67% of lower-risk myelodysplastic syndrome patients in Phase 2 trials, with 56% of transfusion-dependent patients achieving independence. The FDA Fast Track designation accelerates development of a therapy targeting an inflammatory pathway implicated in bone marrow dysfunction.
Regeneration Biomedical's direct-to-brain stem cell therapy received FDA Fast Track designation for Alzheimer's disease, following Phase 1 data showing safety, reductions in phosphorylated tau, and improved amyloid PET measures. This represents a shift toward regenerative approaches that address neurodegeneration at the cellular level rather than symptomatic management alone.
Elysium Health introduced Creatine+, a multi-ingredient formulation combining creatine monohydrate, HMB, and pomegranate polyphenols designed to support muscle energetics, recovery, and cognitive function. The product targets mitochondrial health through evidence suggesting synergistic effects across strength, recovery, and cellular regeneration pathways.
A correction to prior research on irisin—a myokine produced during exercise—clarifies methodological details regarding its role in hippocampal neurogenesis and cognitive resilience. The correction refines understanding of how peripheral exercise signals reach central nervous system structures implicated in age-related cognitive decline.
Aging impairs macrophage phagocytosis through mitochondrial oxidative stress that drives excessive collagen production, which physically inhibits the cytoskeletal dynamics required for immune clearance. Restoring mitochondrial redox balance reverses this dysfunction, directly supporting immune defense in aging organisms.
Researchers developed a method to infer when mitochondrial DNA deletions accumulate in individual cells by analyzing cross-sectional data, enabling earlier detection of cellular aging patterns. This advances the ability to identify age-related mitochondrial dysfunction before it manifests as systemic decline, relevant to understanding and potentially intervening in the accumulation of damage that drives aging.
Senescent cells export abnormal RNA structures (R-loops) through a nuclear transport mechanism involving DDX1 and XPO1 proteins, triggering chronic inflammation via the cGAS-STING pathway. Blocking this export pathway reduces inflammaging and extends healthspan in aging models.
Senescent cells accumulate with age and secrete inflammatory factors that promote abnormal blood vessel growth—a hallmark of tumor progression. This mechanism appears particularly relevant in colitis-associated cancer, where inflammation-driven angiogenesis may resist conventional VEGF-targeted therapies.
Fractyl Health's REVEAL-1 study demonstrates that patients who underwent a single Revita endoscopic procedure after discontinuing GLP-1 therapy retained approximately 78% of their weight loss one year later, with 33% continuing to lose weight—substantially outperforming the typical 15% weight regain seen after medication withdrawal alone. This positions metabolic remodeling of the small intestine as a potential complement to pharmacotherapy, addressing the clinical challenge of weight maintenance once GLP-1 drugs are discontinued.
A preclinical study combining senescent cell clearance with stem cell-based regenerative therapy produced 70% lifespan extension in aged models, substantially outperforming either approach alone. The finding reinforces that addressing aging requires simultaneous intervention across multiple biological pathways rather than single-target strategies.